2. Search Result
Search Result
Results for "

cardiac hypertrophy

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

4

Peptides

16

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0824
    Syringin
    1 Publications Verification

    Eleutheroside B

    		 Autophagy Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Syringin is a main bioactive phenolic glycoside in Acanthopanax senticosus, with anti-osteoporosis activity. Syringin prevents cardiac hypertrophy induced by pressure overload through the attenuation of autophagy .
    Syringin
  • HY-B0124
    Zonisamide
    3 Publications Verification

    AD 810; CI 912

    		 Carbonic Anhydrase Apoptosis Neurological Disease
    Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
    Zonisamide
  • HY-128142
    PKC/PKD-IN-1

    		PKD PKC Cardiovascular Disease
    PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC50 value of 0.6 nM for PKD1. PKC/PKD-IN-1 can attenuate high-salt diet-induced cardiac hypertrophy and can be used in the study of heart failure .
    PKC/PKD-IN-1
  • HY-149453
    MCUF-651

    		Guanylate Cyclase Cardiovascular Disease
    MCUF-651 is an orally active guanylyl cyclase A receptor (GC-A) positive allosteric modulator (PAM) (KD: 397 nM ). MCUF-651 binds to GC-A and selectively enhances the binding of atrial natriuretic peptide (ANP) to GC-A. MCUF-651 enhances ANP-mediated cGMP generation in human cardiac, renal, and fat cells. MCUF-651 inhibits cardiomyocyte hypertrophy .
    MCUF-651
  • HY-139665
    VB124
    5+ Cited Publications

    		 Monocarboxylate Transporter Cardiovascular Disease
    VB124 is an orally active, potent, and selective MCT4 inhibitor. VB124 can specifically inhibit lactate efflux with IC50s of 8.6 nM and 19 nM for lactate import and export in MDA-MB-231 cells, respectively. VB124 is highly selective for MCT4 over MCT1. VB124 can be used for the research of cardiac hypertrophy, heart failure, and metabolism .
    VB124
  • HY-P3054
    S6 peptide

    		Ribosomal S6 Kinase (RSK) Cardiovascular Disease
    S6 peptide is a potentially important lamin kinase. S6 peptide is involved in the process of cardiac hypertrophy induced by mechanical loading. S6 peptide can be activated by many kinds of growth factors .
    S6 peptide
  • HY-114941
    Aladotril

    BP1137

    		 Angiotensin-converting Enzyme (ACE) Neprilysin Cardiovascular Disease
    Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial infarction .
    Aladotril
  • HY-B0124A
    Zonisamide sodium

    AD 810 sodium; CI 912 sodium

    		 Carbonic Anhydrase Apoptosis Cardiovascular Disease Neurological Disease
    Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
    Zonisamide sodium
  • HY-B0124R
    Zonisamide (Standard)

    AD 810 (Standard); CI 912 (Standard)

    		 Reference Standards Carbonic Anhydrase Apoptosis Neurological Disease
    Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
    Zonisamide (Standard)
  • HY-N1181R
    Tamarixetin (Standard)

    4'-O-Methyl Quercetin (Standard)

    		 Reference Standards Endogenous Metabolite ClpP Bacterial Apoptosis Akt Interleukin Related COX JNK p38 MAPK Reactive Oxygen Species (ROS) Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Tamarixetin (Standard) is the analytical standard of Tamarixetin. This product is intended for research and analytical applications. Tamarixetin (4'-O-Methyl Quercetin) is an orally active natural flavonoid derivative of quercetin and caseinolytic protease p (ClpP) inhibitor with anti-inflammatory, antioxidant and antitumor effects. Tamarixetin inhibits the hydrolytic activity of ClpP to the fluorescent substrate Suc-LY-AMC with an IC50 of 49.73 μM, which can be used for the study of Staphylococcus aureus infection. Tamarixetin inhibits tumor cell growth, induces apoptosis, and cell cycle arrest. Tamarixetin prevents cardiac hypertrophy by inhibiting the NFAT and AKT pathways .
    Tamarixetin (Standard)
  • HY-N0787
    Cryptochlorogenic acid
    1 Publications Verification

    4-Caffeoylquinic acid; 4-O-Caffeoylquinic acid

    		 Endogenous Metabolite NF-κB Keap1-Nrf2 mTOR HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    Cryptochlorogenic acid (4-Caffeoylquinic acid) is a naturally occurring phenolic acid compound with oral effectiveness, anti-inflammatory, antioxidant and anti-cardiac hypertrophy effects. Alleviating LPS (HY-D1056) and ISO (HY-B0468) by regulating proinflammatory factor expression, inhibiting NF-κB activity, promoting Nrf2 nuclear transfer, and regulating PI3Kα/Akt/ mTOR / HIF-1α signaling pathway Induced physiological stress response .
    Cryptochlorogenic acid
  • HY-177246A
    Mitotic kinesin-IN-1 hydrochloride

    		Kinesin Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Mitotic kinesin-IN-1 (Example 80) hydrochloride is a Mitotic kinesin inhibitor. Mitotic kinesin-IN-1 hydrochloride inhibits cell proliferation by suppressing mitosis. Mitotic kinesin-IN-1 hydrochloride can be used for cancer, cardiac hypertrophy, immune and inflammatory disorders, fungal infections research .
    Mitotic kinesin-IN-1 hydrochloride
  • HY-177247A
    Mitotic kinesin-IN-2 hydrochloride

    		Kinesin Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Mitotic kinesin-IN-2 (Page 135, fifteenth) hydrochloride is a Mitotic kinesin inhibitor. Mitotic kinesin-IN-2 hydrochloride inhibits cell proliferation by suppressing mitosis. Mitotic kinesin-IN-2 hydrochloride can be used for cancer, cardiac hypertrophy, immune and inflammatory disorders, fungal infections research .
    Mitotic kinesin-IN-2 hydrochloride
  • HY-177248A
    Mitotic kinesin-IN-3 hydrochloride

    		Kinesin Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Mitotic kinesin-IN-3 (Page 135, fourteenth) hydrochloride is a Mitotic kinesin inhibitor. Mitotic kinesin-IN-3 hydrochloride inhibits cell proliferation by suppressing mitosis. Mitotic kinesin-IN-3 hydrochloride can be used for cancer, cardiac hypertrophy, immune and inflammatory disorders, fungal infections research .
    Mitotic kinesin-IN-3 hydrochloride
  • HY-120917
    BRD1172

    ML320

    		 GSK-3 β-catenin Cardiovascular Disease Neurological Disease Cancer
    BRD1172 (ML320) is a selectivity GSK3β inhibitor with an IC50 of 24 nM for GSK3β over CDK5. BRD1172 significantly inhibits GSK3β-mediated Tau phosphorylation in SH-SY5Y cells, and relieves negative regulation by GSK3β on β-catenin degradation and TCF/LEF promoter activities. BRD1172 can be used for Alzheimer’s disease, cardiac hypertrophy and cancers research .
    BRD1172
  • HY-N0617
    Sanggenon C
    2 Publications Verification

    		 Phosphatase ERK NF-κB Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    Sanggenon C, a flavonoid, exerts protective effects against cardiac hypertrophy and fibrosis via suppression of the calcineurin/NFAT2 pathway. Sanggenon C inhibits mitochondrial fission to induce apoptosis by blocking the ERK signaling pathway. Sanggenon C inhibits inducible nitric oxide synthase expression in RAW264.7 cells, and TNF-α-stimulated cell adhesion and VCAM-1 expression, by suppressing NF-κB activity. Sanggenon C possesses antioxidant, anti-inflammatory and antitumor activities .
    Sanggenon C
  • HY-172424
    Delocamten

    		Myosin Cardiovascular Disease
    Delocamten is the inhibitor for cardiac myosin with an IC50 of 1.1 μM. Delocamten can be used in researchs of hypertrophic cardiomyopathy, left ventricular hypertrophy and diastolic dysfunction .
    Delocamten
  • HY-N0824R
    Syringin (Standard)

    Eleutheroside B (Standard)

    		 Reference Standards Autophagy Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Syringin (Standard) is the analytical standard of Syringin. This product is intended for research and analytical applications. Syringin (Eleutheroside B) is an active natural phenolic glycoside possessing various pharmacological activities, including anti-inflammatory, anti-irradiation, anti-osteoporosis and anticancer activities. Syringin also can be used to enhance memory, relieve fatigue, improve human cognition and protect ischemia heart against cerebrovascular damage, etc .
    Syringin (Standard)
  • HY-116196
    17-HETE

    		Na+/K+ ATPase Cytochrome P450 Cardiovascular Disease Inflammation/Immunology
    17-HETE is arachidonic acid metabolite through cytochrome P-450 pathways, which consists of 17R-HETE and 17S-HETE enantiomers. 17-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy .
    17-HETE
  • HY-116050
    17(S)-HETE

    		Cytochrome P450 Na+/K+ ATPase Cardiovascular Disease Inflammation/Immunology
    17S-HETE is arachidonic acid metabolite through cytochrome P-450 pathways. 17S-HETE serves as allosteric activator of the cytochrome P450 1B1 and inhibitor of ATPase, induces cardic hypertrophy .
    17(S)-HETE
  • HY-N1570
    Pterosin B

    		Salt-inducible Kinase (SIK) KLF Amyloid-β Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .
    Pterosin B
  • HY-N1570R
    Pterosin B (Standard)

    		Reference Standards Salt-inducible Kinase (SIK) KLF Amyloid-β Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .
    Pterosin B (Standard)
  • HY-139972
    PROTAC(H-PGDS)-7

    		Molecular Glues Prostaglandin Receptor Cardiovascular Disease
    PROTAC(H-PGDS)-7 is a Hematopoietic prostaglandin D synthase (H-PGDS) molecular glue degrader, with a DC50 of 17.3 pM .
    PROTAC(H-PGDS)-7
  • HY-B0124S2
    Zonisamide-13C6

    AD 810-13C6; CI 912-13C6

    		 Isotope-Labeled Compounds Carbonic Anhydrase Apoptosis Neurological Disease
    Zonisamide- 13C6 (AD 810- 13C6) is 13C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
    Zonisamide-13C6
  • HY-N0787R
    Cryptochlorogenic acid (Standard)

    4-Caffeoylquinic acid (Standard); 4-O-Caffeoylquinic acid (Standard)

    		 Reference Standards Endogenous Metabolite NF-κB Keap1-Nrf2 mTOR HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    Cryptochlorogenic acid (Standard) is the analytical standard of Cryptochlorogenic acid. This product is intended for research and analytical applications. Cryptochlorogenic acid is a natural product.
    Cryptochlorogenic acid (Standard)
  • HY-120657
    9-PAHSA

    		Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
    9-PAHSA
  • HY-169052
    Cyy-272

    		JNK Apoptosis Cardiovascular Disease Inflammation/Immunology
    Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy .
    Cyy-272
  • HY-138051
    TUPS

    		Cytochrome P450 Cancer
    TUPS can inhibit the gene expression of epoxide hydrolase (sEH) and cytochrome P450 (CYP). TUPS can be used in cardiovascular disease-related research .
    TUPS
  • HY-100671
    L002

    		Histone Acetyltransferase STAT Cardiovascular Disease Inflammation/Immunology Cancer
    L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM . L002 binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain, blocks histone acetylation and p53 acetylation, and inhibits STAT3 activation . L002 has the potential for hypertension-induced cardiac hypertrophy and fibrogenesis treatment .
    L002
  • HY-143248
    KR-39038

    		G Protein-coupled Receptor Kinase (GRK) HDAC Cardiovascular Disease
    KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .
    KR-39038
  • HY-N1181
    Tamarixetin
    1 Publications Verification

    4'-O-Methyl Quercetin

    		 Endogenous Metabolite ClpP Bacterial Apoptosis Akt Interleukin Related COX JNK p38 MAPK Reactive Oxygen Species (ROS) Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Tamarixetin (4'-O-Methyl Quercetin) is an orally active natural flavonoid derivative of quercetin and caseinolytic protease p (ClpP) inhibitor with anti-inflammatory, antioxidant and antitumor effects. Tamarixetin inhibits the hydrolytic activity of ClpP to the fluorescent substrate Suc-LY-AMC with an IC50 of 49.73 μM, which can be used for the study of Staphylococcus aureus infection. Tamarixetin inhibits tumor cell growth, induces apoptosis, and cell cycle arrest. Tamarixetin prevents cardiac hypertrophy by inhibiting the NFAT and AKT pathways .
    Tamarixetin
  • HY-12403A
    Talfirastide acetate
    Maximum Cited Publications
    12 Publications Verification

    TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate

    		 Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .
    Talfirastide acetate
  • HY-168438
    ERBB agonist-1

    		EGFR Akt ERK Cardiovascular Disease
    ERBB agonist-1 (Compound EF-1) is an agonist for ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC50 of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H2O2-induced cardiomyocyte death and Ang II (HY-13948)-induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models .
    ERBB agonist-1
  • HY-116050A
    17(R)-HETE

    		Cytochrome P450 Others
    17R-HETE is an arachidonic acid metabolite through cytochrome P-450 pathways. 17R-HETE exhibits efficacy in inducing cardic hypertrophy with less efficiency with compared to 17S-HETE .
    17(R)-HETE
  • HY-174400
    SGLT2-IN-2

    		SGLT SOD Na+/H+ Exchanger (NHE) Autophagy Cardiovascular Disease
    SGLT2-IN-2 (Compound E9) is an inhibitor of SGLT2. SGLT2-IN-2 significantly enhances the inhibition of SGLT2, NHE1, and SOD enzyme activity. SGLT2-IN-2 has protective effect on the glucose-free DMEM-induced injured cardiomyocytes. SGLT2-IN-2 significantly improves cardiac function in TAC-induced HF mice and inhibits cardiomyocyte hypertrophy as well as collagen deposition. SGLT2-IN-2 can ameliorate myocardial tissue damage and enhance mitochondrial autophagy in injured cardiomyocytes, thereby increasing survival rates in HF mice .
    SGLT2-IN-2
  • HY-12403
    Talfirastide
    Maximum Cited Publications
    12 Publications Verification

    TXA127; Angiotensin (1-7); Ang-(1-7)

    		 Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
    Talfirastide
  • HY-158426
    2-APQC
    1 Publications Verification

    		 Sirtuin Cardiovascular Disease
    2-APQC is an orally active and selective agonist of Sirtuin-3 (SIRT3) (Kd=2.756 μM), antagonizes Isoproterenol/ISO (HY-B0468)-induced cytotoxicity. 2-APQC activates the SIRT3-PYCR1 axis to enhance mitochondrial proline metabolism and inhibit the ROS-p38MAPK pathway by inhibiting signaling pathways such as mTOR-p70S6K, JNK, and TGF-β/Smad3. 2-APQC also activates the AMPK-Parkin axis to alleviate myocardial hypertrophy and fibrosis and protect cardiac function. 2-APQC can be used in the study of heart failure .
    2-APQC
  • HY-12403R
    Talfirastide (Standard)

    		Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Talfirastide (Standard) is the analytical standard of Talfirastide. This product is intended for research and analytical applications. Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC50=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .
    Talfirastide (Standard)
  • HY-N1487
    Oleanonic acid
    1 Publications Verification

    3-Oxooleanolic acid

    		 HIV Autophagy Ferroptosis Amyloid-β Infection Neurological Disease Inflammation/Immunology Cancer
    Oleanonic acid (3-Oxooleanolic acid) is an orally available triterpene that has anti-inflammatory and insecticidal properties. In vitro, oleanonic acid can improve oxidative stress, autophagy defects, ferroptosis, mitochondrial damage, and endoplasmic reticulum stress induced by Amyloid-β, and in vivo, it can alleviate myocardial hypertrophy in rats .
    Oleanonic acid
  • HY-128483
    Fusaric acid

    		TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
    Fusaric acid
  • HY-128483R
    Fusaric acid (Standard)

    		TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor Cardiovascular Disease Endocrinology Cancer
    Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
    Fusaric acid (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: